AU2010292225C1 - N-4 ( - ( ( 3- ( 2 -amino-4 pyrimidinyl) -2 -pyridinyl) oxy) phenyl) -4- (4-methyl-2-thienyl) -1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer - Google Patents

N-4 ( - ( ( 3- ( 2 -amino-4 pyrimidinyl) -2 -pyridinyl) oxy) phenyl) -4- (4-methyl-2-thienyl) -1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer Download PDF

Info

Publication number
AU2010292225C1
AU2010292225C1 AU2010292225A AU2010292225A AU2010292225C1 AU 2010292225 C1 AU2010292225 C1 AU 2010292225C1 AU 2010292225 A AU2010292225 A AU 2010292225A AU 2010292225 A AU2010292225 A AU 2010292225A AU 2010292225 C1 AU2010292225 C1 AU 2010292225C1
Authority
AU
Australia
Prior art keywords
cancer
amg
tumor
agent
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2010292225A
Other languages
English (en)
Other versions
AU2010292225A1 (en
AU2010292225B2 (en
Inventor
Richard Kendall
Marc Payton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43216900&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2010292225(C1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AU2010292225A1 publication Critical patent/AU2010292225A1/en
Application granted granted Critical
Publication of AU2010292225B2 publication Critical patent/AU2010292225B2/en
Publication of AU2010292225C1 publication Critical patent/AU2010292225C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2010292225A 2009-09-11 2010-09-09 N-4 ( - ( ( 3- ( 2 -amino-4 pyrimidinyl) -2 -pyridinyl) oxy) phenyl) -4- (4-methyl-2-thienyl) -1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer Active AU2010292225C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24152709P 2009-09-11 2009-09-11
US61/241,527 2009-09-11
PCT/US2010/048247 WO2011031842A1 (en) 2009-09-11 2010-09-09 N-4 ( - ( ( 3- ( 2 -amino-4 pyrimidinyl) -2 -pyridinyl) oxy) phenyl) -4- (4-methyl-2-thienyl) -1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer

Publications (3)

Publication Number Publication Date
AU2010292225A1 AU2010292225A1 (en) 2012-04-12
AU2010292225B2 AU2010292225B2 (en) 2012-12-13
AU2010292225C1 true AU2010292225C1 (en) 2013-06-27

Family

ID=43216900

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010292225A Active AU2010292225C1 (en) 2009-09-11 2010-09-09 N-4 ( - ( ( 3- ( 2 -amino-4 pyrimidinyl) -2 -pyridinyl) oxy) phenyl) -4- (4-methyl-2-thienyl) -1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer

Country Status (34)

Country Link
US (1) US20120028917A1 (https=)
EP (2) EP2475368B1 (https=)
JP (1) JP5851403B2 (https=)
KR (1) KR20120082896A (https=)
CN (1) CN102869361A (https=)
AU (1) AU2010292225C1 (https=)
BR (1) BR112012008325A2 (https=)
CA (1) CA2773838C (https=)
CL (1) CL2012000640A1 (https=)
CR (1) CR20120171A (https=)
DK (1) DK2475368T3 (https=)
EA (1) EA020526B1 (https=)
ES (1) ES2528485T3 (https=)
HK (1) HK1205457A1 (https=)
HR (1) HRP20150104T1 (https=)
HU (1) HUE024568T2 (https=)
IL (1) IL218569A0 (https=)
MA (1) MA33658B1 (https=)
ME (1) ME02048B (https=)
MX (1) MX2012003041A (https=)
NZ (1) NZ598758A (https=)
PE (1) PE20120895A1 (https=)
PH (1) PH12012500504A1 (https=)
PL (1) PL2475368T3 (https=)
PT (1) PT2475368E (https=)
RS (1) RS53807B1 (https=)
SG (1) SG179102A1 (https=)
SI (1) SI2475368T1 (https=)
SM (1) SMT201500028B (https=)
TN (1) TN2012000110A1 (https=)
TW (1) TW201121956A (https=)
UA (1) UA107675C2 (https=)
WO (1) WO2011031842A1 (https=)
ZA (1) ZA201202472B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015518053A (ja) * 2012-05-31 2015-06-25 アムジエン・インコーポレーテツド 癌の治療のためのａｍｇ９００の使用
CN103664737A (zh) * 2012-09-25 2014-03-26 杨子娇 一类治疗房角狭窄的化合物及其用途
US9963701B2 (en) 2013-09-30 2018-05-08 Korea Institute Of Radiological & Medical Sciences Pharmaceutical composition for treatment of radiation- or drug-resistant cancer comprising HRP-3 inhibitor
HRP20220718T1 (hr) 2013-11-11 2022-09-30 Amgen Inc. Kombinacijska terapija uključujući inhibitor mdm2 i jedan ili više dodatnih farmaceutski aktivnih sredstava za liječenje raka
US10053452B2 (en) 2013-12-03 2018-08-21 Amgen Inc. Crystalline forms of N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine salts and uses thereof
SG11201606869TA (en) * 2014-02-21 2016-09-29 Frost Biolog Inc Antimitotic amides for the treatment of cancer and proliferative disorders
CN109313197A (zh) * 2016-04-15 2019-02-05 费利克斯疗法公司 使用静止细胞靶向和有丝分裂抑制剂的用于治疗肿瘤的组合
EA201992781A1 (ru) 2017-05-22 2020-04-01 Эмджен Инк. Ингибиторы g12c kras и способы их применения
MA50077A (fr) 2017-09-08 2020-07-15 Amgen Inc Inhibiteurs de kras g12c et leurs procédés d'utilisation
WO2019213516A1 (en) 2018-05-04 2019-11-07 Amgen Inc. Kras g12c inhibitors and methods of using the same
US20190375749A1 (en) 2018-06-11 2019-12-12 Amgen Inc. Kras g12c inhibitors and methods of using the same
ES3060664T3 (en) 2018-06-12 2026-03-27 Amgen Inc Kras g12c inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
NZ782284A (en) 2019-05-21 2024-11-29 Amgen Inc Solid state forms

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070185111A1 (en) * 2006-01-23 2007-08-09 Cee Victor J Aurora kinase modulators and method of use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060178318A1 (en) * 2003-07-03 2006-08-10 Shubha Anand Use of aurora kinase inhibitors for reducing the resistance of cancer cells
AU2007208351C1 (en) * 2006-01-23 2011-07-07 Amgen Inc. Aurora kinase modulators and method of use
UA93538C2 (en) * 2006-01-23 2011-02-25 Амген Инк. Aurora kinase modulators and method of use
GB0609621D0 (en) * 2006-05-16 2006-06-21 Astrazeneca Ab Novel co-crystal
GB0609619D0 (en) * 2006-05-16 2006-06-21 Astrazeneca Ab Combination

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070185111A1 (en) * 2006-01-23 2007-08-09 Cee Victor J Aurora kinase modulators and method of use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HARRINGTON, E. A., et al., "VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo," Nature Medicine, March 2004, Vol. 10, No. 3, pages 262-267. *
MOUNTZIOS, G., et al., "Aurora kinases as targets for cancer therapy," Cancer Treatment Reviews, 2008, Vol. 34, No. 2, page 175-182. *

Also Published As

Publication number Publication date
EP2818170B1 (en) 2018-12-05
EP2818170A1 (en) 2014-12-31
JP2013504582A (ja) 2013-02-07
EA201270383A1 (ru) 2013-04-30
CA2773838A1 (en) 2011-03-17
IL218569A0 (en) 2012-05-31
RS53807B1 (sr) 2015-06-30
JP5851403B2 (ja) 2016-02-03
PE20120895A1 (es) 2012-08-19
CR20120171A (es) 2012-08-09
PL2475368T3 (pl) 2015-05-29
TN2012000110A1 (en) 2013-09-19
TW201121956A (en) 2011-07-01
NZ598758A (en) 2013-12-20
WO2011031842A1 (en) 2011-03-17
HRP20150104T1 (xx) 2015-03-13
US20120028917A1 (en) 2012-02-02
MA33658B1 (fr) 2012-10-01
MX2012003041A (es) 2012-06-27
CA2773838C (en) 2016-05-31
EP2475368A1 (en) 2012-07-18
SI2475368T1 (sl) 2015-03-31
EP2475368B1 (en) 2014-12-17
HK1173655A1 (en) 2013-05-24
EA020526B1 (ru) 2014-11-28
ZA201202472B (en) 2012-12-27
AU2010292225A1 (en) 2012-04-12
DK2475368T3 (en) 2015-03-09
PT2475368E (pt) 2015-02-10
ME02048B (me) 2015-05-20
KR20120082896A (ko) 2012-07-24
HK1205457A1 (en) 2015-12-18
HUE024568T2 (hu) 2016-02-29
ES2528485T3 (es) 2015-02-10
CN102869361A (zh) 2013-01-09
PH12012500504A1 (en) 2015-04-29
SG179102A1 (en) 2012-04-27
UA107675C2 (xx) 2015-02-10
CL2012000640A1 (es) 2012-09-21
BR112012008325A2 (pt) 2017-08-29
AU2010292225B2 (en) 2012-12-13
SMT201500028B (it) 2015-03-05

Similar Documents

Publication Publication Date Title
AU2010292225C1 (en) N-4 ( - ( ( 3- ( 2 -amino-4 pyrimidinyl) -2 -pyridinyl) oxy) phenyl) -4- (4-methyl-2-thienyl) -1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer
JP6433085B2 (ja) がんの処置に使用するための２−アセチルナフト［２，３−ｂ］フラン−４，９−ジオン
US20090054415A1 (en) Combinations, methods and compositions for treating cancer
AU2014344789B2 (en) Pharmaceutical combinations for the treatment of cancer
KR20170017932A (ko) Ｍｄｍ２ 억제제의 간헐적 투여
KR20070064414A (ko) 세포 증식 제어를 위한 ｃｈｋ1 억제제의 용도
AU2015209095A1 (en) Novel methods for treating cancer
EP3560497A1 (en) Compositions and methods for drug-sensitization or inhibition of a cancer cell
US20130310448A1 (en) Methods and compositions for inhibition of atr and fancd2 activation
US20190133998A1 (en) Treatment of tumors with inhibitors of cxcl12 signaling and subtherapeutic amounts of chemotherapeutic agents
HK1173655B (en) N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer
EP3070092B1 (en) 3-phenyl-thiazolo[3,2-a]benzimidazole derivatives as aldehyde dehydrogenase 1 (aldh-1) modulators for the treatment of breast cancer or leukemia, and for manipulating cultured aldh-1 positive breast cancer or leukemia cells
Lindamulage Characterisation of CTR-17 and CTR-20, novel chalcone derivatives that inhibit tubulin polymerisation activity
WO2010085462A1 (en) Method for treating triple negative breast cancer

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 31 JAN 2013 .

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 31 JAN 2013

FGA Letters patent sealed or granted (standard patent)